Related Experiment Video

Updated: May 1, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

8.4K

Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells

Esther Z Chen1, Blake A Jacobson, Manish R Patel

  • 1Department of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.

Investigational New Drugs
|April 9, 2014
PubMed

Insights

This study shows that 4Ei-1, a novel prodrug, effectively reduces mesothelioma cell proliferation and colony formation by disrupting the eIF4F complex. It also enhances the efficacy of pemetrexed in mesothelioma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Deranged cap-mediated translation is crucial in the development and progression of human cancers, including mesothelioma.
  • Targeting the eukaryotic initiation factor 4F (eIF4F) complex offers a potential therapeutic strategy for mesothelioma.

Purpose of the Study:

  • To assess the efficacy of disrupting the eIF4E-mRNA-cap interaction using 4Ei-1 as a novel therapy for mesothelioma.
  • To evaluate the combination therapy of 4Ei-1 with pemetrexed in mesothelioma treatment.

Main Methods:

  • Mesothelioma cells were treated with 4Ei-1, a prodrug converted to 7-benzyl guanosine monophosphate (7Bn-GMP), which displaces capped mRNAs from the eIF4F complex.
  • Colony formation, cell proliferation, and eIF4F complex activation were measured in response to 4Ei-1 treatment, alone and in combination with pemetrexed.

Main Results:

  • 4Ei-1 treatment demonstrated a dose-dependent decrease in mesothelioma colony formation and cell viability.
  • Combination therapy with pemetrexed further reduced colony formation.
  • Exposure to 4Ei-1 diminished the association of the eIF4F complex with the mRNA cap.

Conclusions:

  • 4Ei-1 is a promising novel prodrug for mesothelioma therapy, reducing proliferation and colony formation.
  • 4Ei-1 effectively disrupts the eIF4F complex-mRNA cap interaction.
  • 4Ei-1 sensitizes mesothelioma cells to pemetrexed, suggesting a role in combination therapies.

More Related Videos

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

7.5K
A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

594

Related Concept Videos

Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
24.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K